Atrium Therapeutics
RNA | NASDAQ
$6.43
-$1.08 (-14.38%)
At close: Nov 16, 2026, 4:00 PM ET
$6.52
+$0.09 (+1.40%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-14.38%
(1D)No price chart data available for 1D timeframe.
Rating
40.8
Fundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #501/1021 (Top 49%)
Key Statistics
Market Data
Market Cap $138.7M
1D Range
6.36 7.69
52W Range
6.36 16.54
Valuation (TTM)
PE -1.57
PB 0.68
EV/EBITDA 1.02
Valuation (NTM)
Forward PE N/A
Forward PEG 0.07
Price Target $22.50
Cash Flow
FCF Yield -59.9%
SBC Adj. FCF Yield -63.3%
SBC Impact -5.6%
Margins
Gross Margin 42.2%
Operating Margin -243.6%
FCF Margin -214.1%
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y N/A |
N/A
FCF 3Y | 5Y N/A |
N/A
Returns
ROA -33.8%
ROE -41.4%
ROIC -39.4%
Financial Health
Net Cash
$232.07M
Current Ratio 10.46
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the hea...
Sector Healthcare
Industry Biotechnology
Employees 511
IPO Date Feb 27, 2026
Website www.atriumtherapeutics.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
1
Consensus
Buy
Price Target
$20.00
Upside
+211.04%
Buy (1)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove RNA